Charge-Free DNA Delivery Molecule Boosts Cellular Uptake 14-Fold in Mouse Experiments

Getting DNA into cells sounds deceptively straightforward. In practice, it is one of the core technical challenges of modern gene therapy and genetic medicine. Cell membranes are selective barriers, and unprotected DNA dissolves rapidly in biological fluids before reaching any target. The field has spent decades developing vehicles - carriers that protect DNA in transit and help it cross into cells - but most existing approaches come with trade-offs that limit their clinical utility.

A team at Tokyo Metropolitan University led by Professor Shoichiro Asayama has developed a new carrier that sidesteps the most problematic of those trade-offs: the reliance on positive charge. Their results, achieved in mouse models, show a 14-fold improvement in cellular DNA uptake compared to unprotected DNA, using a neutral molecule rather than a charged one.

The Problem With Positive Charge

The dominant approach to DNA delivery has long used positively charged polymers - cationic materials that bind to the negatively charged DNA through electrostatic attraction, forming compact complexes that cells can engulf. This works reasonably well in laboratory settings, but positive charge creates serious problems in the body.

Cationic materials trigger inflammation at injection sites. They attract negatively charged molecules indiscriminately - including components of the extracellular matrix in muscle tissue - forming large aggregates that cannot enter cells effectively. In intramuscular injection, a common delivery route for genetic vaccines and therapies, this nonspecific binding substantially reduces delivery efficiency and increases local tissue damage.

Researchers have tried to solve this with lipid nanoparticles, which encapsulate nucleic acids in fat-based shells that can fuse with cell membranes. This technology underpins the mRNA vaccines developed during the COVID-19 pandemic. But lipid nanoparticles have their own limitations: they are sensitive to temperature, require specific manufacturing conditions, and some formulations still produce inflammatory responses.

A Different Binding Strategy

Asayama's team took a mechanistically different approach. They synthesized a molecule consisting of polyethylene glycol (PEG) - a well-tolerated, biologically inert polymer used widely in drug formulations - with a single thymine base attached at one end. Thymine is one of the four nucleobases that make up DNA, and it forms hydrogen bonds with adenine bases in the complementary DNA strand.

The challenge was creating conditions for this weak interaction to form. The solution was a process called annealing: heating the plasmid DNA gently causes the double helix to partially unwind, exposing adenine bases. In the presence of the thymine-PEG molecule, the exposed adenines can form hydrogen bonds with the thymine terminus of the PEG strand, creating a complex between the delivery molecule and the DNA without requiring any charge-based interaction.

By varying the ratio of thymine-PEG strands to DNA molecules, the team optimized their formulation for maximum cellular uptake. The resulting complex - which they call a single nucleobase-terminal complex (SNTC) - improved cellular DNA delivery in mouse cells by a factor of up to 14 compared to naked DNA alone.

What This Means and What Remains Unknown

A 14-fold improvement in cellular uptake in a mouse model is an encouraging laboratory result, not a clinical advance. The study tested the SNTC in mouse experiments; whether the same enhancement holds in larger animals, in different tissue types, or in humans is not yet established. The mechanisms by which the neutral complex is taken up by cells - whether through specific cellular machinery or general endocytosis - are not fully characterized, which matters for understanding which cell types the approach will work with and which it will not.

The absence of positive charge is the SNTC's most distinctive feature and its most clinically relevant advantage. Inflammation at injection sites is not merely uncomfortable - it is a meaningful safety signal that regulators scrutinize and that can disqualify otherwise promising therapies. A carrier that delivers comparable or better DNA uptake without triggering this response would have real development advantages.

Plasmid DNA, the specific form of DNA targeted in this work, is used in DNA vaccines, gene therapy vectors, and research tools. Its delivery efficiency in muscle tissue has long been a limiting factor for these applications, particularly for genetic vaccines where intramuscular injection is the standard route. The SNTC approach, if it holds up in further testing, could improve the practical utility of DNA-based medical tools across a range of applications.